Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Blueprint Medicines Corporation
Reveal Pharmaceuticals Inc.
Seattle Children's Hospital
National Institutes of Health Clinical Center (CC)
Cedars-Sinai Medical Center
Thomas Jefferson University
Thomas Jefferson University
Dana-Farber Cancer Institute
St. Jude Children's Research Hospital
National Cancer Institute (NCI)
BeiGene
National Cancer Institute (NCI)
Children's Oncology Group
Children's Oncology Group
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
Mayo Clinic
Children's Oncology Group
Radiation Therapy Oncology Group
Radiation Therapy Oncology Group
Blaze Bioscience Inc.
St. Jude Children's Research Hospital
Universitätsmedizin Mannheim
Celgene
The Hospital for Sick Children
Memorial Sloan Kettering Cancer Center
Emory University
National Cancer Institute (NCI)
UNICANCER
Masonic Cancer Center, University of Minnesota
St. Jude Children's Research Hospital
Norwegian University of Science and Technology
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
Stanford University
Children's Oncology Group
Children's Oncology Group
National Institutes of Health Clinical Center (CC)
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
Children's Oncology Group
National Cancer Institute (NCI)
Children's Hospital Los Angeles
Radiation Therapy Oncology Group
Eisai Inc.
Canadian Cancer Trials Group
Canadian Cancer Trials Group
Mayo Clinic